Woodcock Doesn't Want To Be Commissioner – But Has Some Ideas
Executive Summary
CDER director believes some management improvements could be made in the executive suite, but she does not aspire to run FDA.
You may also be interested in...
Woodcock's Legacy: CDER Organizational Improvements
In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.
No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama
The pharmaceutical industry has an unusual new ally in its effort to achieve some of its goals during the presidential transition: Rep. Bart Stupak, D-Mich
FDA NOMINATION OF JANET WOODCOCK, MD, AS NEW CDER DIRECTOR
FDA NOMINATION OF JANET WOODCOCK, MD, AS NEW CDER DIRECTOR is awaiting final clearance at HHS. Woodcock, currently director of FDA's Center for Biologics Evaluation & Research's Office of Therapeutics Research and Review, was selected from a short list of candidates for the Center for Drug Evaluation & Research post submitted by a search committee to Deputy Commissioner for Operations Jane Henney, MD, in early November.